Research Study

Establishing an Imaging Biomarker for Disease Progression in Multiple Sclerosis
Principal Investigator 
Shannon Kolind

Overview

Body Locations and Systems 
Multiple Sclerosis
Diagnosis and Therapy 
Diagnostic Imaging
Status 
Recruiting
Study Start/End 
Jun 1, 2017 to Jun 30, 2020
Locations 
UBC Hospital
Name/Title 
Shawna Able, Research Assistant
Phone 
604-822-1650
Purpose of Study 

MS is a disabling neurological disease with a highly variable clinical course including acute disability (relapses when symptoms appear or worsen) and disease progression (steady accumulation of disability in the absence of relapses). There is currently no approved treatment for progressive MS. A principal pathology of MS is the destruction of myelin, which surrounds nerves to speed up signal conduction. We have developed a magnetic resonance imaging technique that provides quantitative measurements of myelin. Our aim is to establish myelin water imaging as a biomarker for disease progression, allowing efficient clinical trials to establish effective treatment options for progressive MS. 

Eligibility 

People with clinically diagnosed multiple sclerosis as well as healthy controls.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.